These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 34120321)

  • 21. Analysis of the US FDA adverse event reporting system to identify adverse cardiac events associated with hydroxychloroquine in older adults.
    Nishtala PS; Gill S; Chyou TY
    Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1689-1695. PubMed ID: 33078448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does eltrombopag lead to thrombotic events? A pharmacovigilance study of the FDA adverse event reporting system.
    Jiang JJ; Zhao B; Li J
    J Clin Pharm Ther; 2022 Oct; 47(10):1556-1562. PubMed ID: 35644838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibacterial-associated acute kidney injury among older adults: A post-marketing surveillance study using the FDA adverse events reporting system.
    Chinzowu T; Chyou TY; Nishtala PS
    Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1190-1198. PubMed ID: 35670078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study.
    Huang J; Cai J; Ye Q; Jiang Q; Lin H; Wu L
    BMJ Open; 2023 Aug; 13(8):e071456. PubMed ID: 37536976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS).
    Mytheen S; Varghese A; Joy J; Shaji A; Tom AA
    Expert Opin Drug Saf; 2023; 22(10):985-994. PubMed ID: 37294921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
    Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
    Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection and analysis of signals of adverse events of memantine based on the US food and drug administration adverse event reporting system.
    Zhang W; Chen M; Cai X; Zhang M; Hu M; Hu Y; Yang Y; Zhu J; Du Y; Yang C
    Expert Opin Drug Saf; 2024 May; 23(5):617-625. PubMed ID: 38568141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Data mining of the public version of the FDA Adverse Event Reporting System.
    Sakaeda T; Tamon A; Kadoyama K; Okuno Y
    Int J Med Sci; 2013; 10(7):796-803. PubMed ID: 23794943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab.
    Chen Z; Li M; Li S; Li Y; Wu J; Qiu K; Yu X; Huang L; Chen G
    Expert Opin Drug Saf; 2023 Apr; 22(4):339-342. PubMed ID: 36178002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database.
    Altebainawi AF; Alfaraj LA; Alharbi AA; Alkhuraisi FF; Alshammari TM
    Ther Adv Drug Saf; 2023; 14():20420986231154075. PubMed ID: 36875514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Moreland-Head LN; Coons JC; Seybert AL; Gray MP; Kane-Gill SL
    J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):341-348. PubMed ID: 33403858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs.
    Garg V; Raisch DW; McKoy JM; Trifilio SM; Holbrook J; Edwards BJ; Belknap SM; Samaras AT; Nardone B; West DP
    Expert Opin Drug Saf; 2013 May; 12(3):299-307. PubMed ID: 23480866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
    Wittayanukorn S; Qian J; Johnson BS; Hansen RA
    J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Agranulocytosis and secondary infection related to JAK inhibitors and IL-6 receptor blockers: a disproportionality analysis using the US Food and drug administration adverse event reporting system.
    Wei C; Yin W; Hu T; Zhang J; Dan H; Wu B
    Front Pharmacol; 2023; 14():1323240. PubMed ID: 38264533
    [No Abstract]   [Full Text] [Related]  

  • 37. Assessment of adverse events of the novel cardiovascular drug vericiguat: a real-world pharmacovigilance study based on FAERS.
    Rao J; Chen X; Liu Y; Wang X; Cheng P; Wang Z
    Expert Opin Drug Saf; 2024 Jul; ():1-9. PubMed ID: 39021273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
    Scott IC; Hider SL; Scott DL
    Drug Saf; 2018 Jul; 41(7):645-653. PubMed ID: 29500799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database.
    Jiang Y; Zhou L; Shen Y; Zhou Q; Ji Y; Zhu H
    J Affect Disord; 2024 Feb; 346():223-229. PubMed ID: 37956832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dropped head syndrome: a rare adverse drug reaction identified in the FDA adverse event reporting system and review of case reports in the literature.
    Liu X; Zhao X; He Y; Tang Y; Yan XL; Zhao B; Dai Y
    Expert Opin Drug Saf; 2022 Oct; 21(10):1329-1336. PubMed ID: 35315301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.